CHEBI:8228 Actos Duetact Pioglitazone US20240091210, Compound Pioglitazone BDBM50103521
US20250064791, Compound Pioglitazone BDBM724000
5-{4-[2-(5-Ethyl-pyridin-2-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione; hydrochloride(pioglitazone) 5-{4-[2-(5-Ethyl-pyridin-2-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione; hydrochloride U-72107A Actos Pioglitazone PIOGLITAZONE HYDROCHLORIDE BDBM50111005 CHEMBL1715
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione PIOGLITAZONE PIOGLITAZONE HYDROCHLORIDE 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione BDBM50049240 CHEMBL595
- DeWitt, S; Jacques, V; van der Ploeg, LH Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone US Patent US10188639 (2019)
- Mosure, SA; Shang, J; Eberhardt, J; Brust, R; Zheng, J; Griffin, PR; Forli, S; Kojetin, DJ Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARĪ³ Drug Pioglitazone. J Med Chem 62: 2008-2023 (2019)